
About Us
Company founded Tens of millions USD of A round raised Preliminary R&D pipeline established
Opening of InxMed Shanghai & Beijing offices
IN10018 Received US FDA IND Approval
Achieved clinical collaboration with Roche for IN10018 co-development
IN10018 Phase I Clinical Trial in China approved
Achieved clinical collaboration with Merck for IN10018 co-development
First patient enrolled in the US
Investigational New Drug (IND) application approved for IN10018 combined with chemotherapy for the treatment of high-grade serous ovarian cancer
First patient enrolled in China
Closed 130 million RMB of A+ round
Opening of InxMed R&D and Translational Research Center
IN10018 Received US FDA Fast Track Designation
Published the result of IN10018 synergized with KRAS G12C Inhibitors to improve treatment outcomes for KRAS G12C mutant cancers
Closed US $50M Series B Financing
IN10018 Received NMPA Breakthrough Designation
Closed US $15M Series B+ Financing
Announced that result of an open-label phase Ib trial of IN10018 in PROC in ASCO 2022
Announced first patient dosed in pivotal phase 2 study of IN10018 in PROC
Released data demonstrating IN10018 therapeutic potential in metastatic melanoma at SMR 2022
Received approval to initiate phase I clinical trial in China for OMTX705
Released data at 14th Annual World ADC highlighting synergy of IN10018 with ADCs and novel stroma targeting pipeline
Released data demonstrating IN10018 trending toward survival benefit for PROC and TNBC at ESMO 2023
Entered license agreement with Escugen to develop next-generation ADCs
Released Positive Phase Ib/II Results for IN10018 in Combination with Garsorasib in 1L NSCLC with KRAS G12C Mutation
Released data IN10018 improving therapeutic window of ADC at 15th Annual World ADC
Received Breakthrough Therapy Designation by China NMPA for 1L NSCLC with KRAS G12C Mutation

Time of issue : 2022-05-13 15:16:50

Time of issue : 2022-05-13 15:22:06


Time of issue : 2022-05-13 16:04:11

Time of issue : 2022-05-13 16:04:30

Time of issue : 2022-05-13 16:08:21

Time of issue : 2022-05-13 16:09:29


Time of issue : 2022-05-13 16:11:21

Time of issue : 2022-05-13 16:12:30

Time of issue : 2022-05-13 16:13:28


Time of issue : 2022-05-25 08:55:48


Time of issue : 2022-05-25 09:02:52

Time of issue : 2022-11-15 11:33:01

Time of issue : 2022-11-15 11:38:08

Time of issue : 2024-01-16 11:05:51

Time of issue : 2024-01-16 11:06:34

Time of issue : 2024-01-16 11:07:26

Time of issue : 2024-01-16 11:08:21

Time of issue : 2025-01-14 14:51:47

Time of issue : 2025-01-14 14:52:02

Time of issue : 2025-01-14 14:52:19

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
CopyRight © 2022 InxMed All Rights Reserved.